-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion Therapeutics doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer

PUBT·09/30/2026 12:06:34
Silexion Therapeutics doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer
  • Silexion Therapeutics dosed the first patient in a global Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer.
  • No efficacy results have been presented; preliminary clinical readouts are expected in the future as enrollment expands.
  • Study tests SIL204 with standard chemotherapy versus chemotherapy alone in newly diagnosed, KRAS-mutated, unresectable Stage 3 patients.
  • Program aims to improve response and survival by combining local tumor delivery with systemic dosing to address disease beyond the primary tumor.
  • First dosing occurred at Tel Aviv Sourasky Medical Center; additional sites in Israel and Germany are moving toward activation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONEFULLFEED1001275297) on September 30, 2026, and is solely responsible for the information contained therein.